Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia

Phase 3

Terminated

• Conditions: Cervical Intraepithelial Neoplasia
• Interventions: Drug: Topical Imiquimod; Procedure: Conization

• Registration Number: NCT01283763
• Lead Sponsor: Medical University of Vienna

Brief Summary

The purpose of this study is to investigate the non-inferiority of a topical Imiquimod therapy in patients with persistent CIN 2/3 when compared to standard therapy, i.e. conization A randomized, controlled, non-inferiority AGO-Austria trial

Detailed Description

Background: Alternatives to surgery are needed for the treatment of cervical intraepithelial neoplasia (CIN). CIN is associated with persistent human papillomavirus (HPV) infection and is known to be a potential precursor of cervical cancer. The incidence of CIN has been increasing during the last decades, especially among young women. Patients diagnosed with (persistent) high-grade CIN (CIN2/3) are treated with conization. Conization can be regarded as a safe procedure but peri- and postoperative complications (infections, bleeding, preterm birth) occur. This raises the need for a conservative treatment alternative for patients with high-grade CIN. Preliminary data: Imiquimod (IMQ), a toll-like receptor 7 agonist, is an immune modulating substance approved for the therapy of superficial skin lesions (e.g. basalioma, actinic keratosis) and HPV associated disease (e.g. anogenital condylomata acuminata and vulvar intraepithelial neoplasia). In a randomized, placebo-controlled phase II trial, we previously showed that topical IMQ therapy is an efficacious and feasible treatment for selected patients with CIN 2/3. Methods: In the present open, randomized, non-inferiority trial 500 women with CIN 2/3 will be included. This non-profit, patient-oriented clinical research project will be conducted as an Austrian Gynecologic Oncology Group (AGO-Austria) trial. Participants will be randomized to either 16 weeks treatment with topical IMQ (new treatment) or to standard therapy i.e. conization (active control). This study investigates the non-inferiority of the new treatment, compared to surgical standard treatment. The primary endpoint is the rate of successful treatment, defined as negative HPV test result six months after treatment start. Six months after start of therapy the primary study endpoint is assessed using HPV genotyping. In addition clinical examinations including colposcopy, HPV genotyping, cytology, and if indicated colposcopy-guided biopsies of the uterine cervix will be performed. In addition, rates of CIN persistence/recurrence 6, 12, 18, and 24 months after start of the treatment and rates of negative HPV test results 12 and 24 months after start of the treatment will be evaluated in both treatment groups.

Rationale: The need for a conservative treatment modality for patients diagnosed with CIN is obvious, as many young women need surgical treatment. In this randomized controlled, trial we will investigate the non-inferiority of a topical IMQ treatment compared to surgical standard treatment in selected patients diagnosed with CIN 2/3.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2011-01-21
• Study First Submitted QC: 2011-01-25
• Study First Posted: 2011-01-26
• Study Start: 2013-05
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-30
• Last Update Posted: 2016-11-01
• Primary Completion: 2017-09
• Study Completion: 2018-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 95

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Topical Imiquimod	Topical Imiquimod	16 weeks topical Imiquimod
Conization	Conization	Large loop excision of the transformation zone

Primary Outcome Measures

Name	Time	Method
HPV clearance	6 months after treatment completion	non-inferiority of experimental treatment (Imiquimod) to active control (conization)

Secondary Outcome Measures

Name	Time	Method
HPV clearance	12 and 24 months after treatment completion
Rates of CIN remission/regression and/or CIN persistence/regression after treatment	6, 12, and 24 months after treatment completion	Histologic outcome

Trial Locations

Locations (1)

Medical University of Vienna; 🇦🇹 Vienna, Austria